• Cytochalasin B (NSC 107658): Elevating Cytoskeletal Research

  2026-07-13

  Cytochalasin B (NSC 107658) stands as the gold-standard cytoskeletal research tool, offering unmatched precision for dissecting actin-driven processes. Discover how advanced protocols, troubleshooting insights, and real-world assay optimizations power reliable results in cell division, motility, and toxicology studies.

• GSH-Responsive MOF Nanoparticles Unify Photothermal and Immu

  2026-07-13

  This study reports the development of glutathione-responsive, indocyanine green-loaded MOF nanoparticles modified with a PD-1 inhibitory peptide for synergistic photothermal and immunotherapy in melanoma. The approach demonstrates targeted immune checkpoint blockade and enhanced tumor ablation, highlighting a promising strategy for advanced nanomedicine.

• Proteoform-Specific Drug Interactions in Native Cell Signali

  2026-07-12

  The referenced study pioneers the direct analysis of proteoform-specific drug interactions within native cell membrane environments using advanced native mass spectrometry. By mapping how alternative splicing and post-translational modifications shape protein–ligand interactions, the work sets new standards for precision pharmacology and highlights the need for tools capable of resolving proteoform complexity in drug discovery.

• D-Lin-MC3-DMA: Shaping the Next Era of RNA Therapeutics

  2026-07-10

  Explore how D-Lin-MC3-DMA, an advanced ionizable cationic liposome, is redefining the landscape of lipid nanoparticle-mediated siRNA and mRNA delivery. This article delivers mechanistic depth, strategic insight, and practical guidance for translational researchers seeking to harness D-Lin-MC3-DMA in hepatic gene silencing, mRNA vaccine innovation, and cancer immunochemotherapy, drawing on leading literature and predictive modeling advances.

• ONX-0914 (PR-957): Precision Immunoproteasome Inhibition Wor

  2026-07-09

  ONX-0914 (PR-957) unlocks targeted immunoproteasome inhibition for autoimmune and neuroimmune research, enabling reproducible cytokine blockade and novel exploration of synaptic plasticity. This guide translates the latest experimental findings into optimized protocols and advanced troubleshooting strategies for in vitro and in vivo models.

• mRNA Vaccination Protects Dairy Cows from H5N1: A Landmark S

  2026-07-09

  This study demonstrates the robust efficacy and safety of a hemagglutinin-based mRNA vaccine in protecting lactating dairy cows against H5N1 influenza virus. The findings establish a critical proof-of-concept for mRNA vaccine application in large livestock, with implications for animal and public health.

• LY2886721 BACE Inhibitor: Applied Workflows in Alzheimer’s R

  2026-07-08

  LY2886721 empowers Alzheimer's research with nanomolar BACE1 inhibition, facilitating reproducible amyloid beta reduction in both cell and animal models. Its synaptic safety at moderate doses and robust performance make it a workflow cornerstone for studying amyloid pathology.

• Bispecific Antibodies Targeting Orthopoxviruses: Characteriz

  2026-07-08

  This study systematically characterizes monoclonal antibodies against the M1R and B6R proteins of mpox virus, demonstrating that antibody cocktails and novel bispecific designs provide enhanced protection against orthopoxvirus infection. The research delivers critical epitope mapping, functional validation, and translational routes toward broad-spectrum antiviral antibody therapies.

• Cytochalasin B: Strategic Leverage for Cytoskeletal Drug Dis

  2026-07-07

  Explore how Cytochalasin B (NSC 107658) empowers translational researchers to dissect actin-dependent cellular mechanisms, design advanced assays, and inform drug discovery targeting the cytoskeleton. This thought-leadership piece bridges mechanistic insight and evidence-based protocol guidance, spotlighting biological rationale, competitive innovations, and translational relevance, while referencing pivotal studies on pathogen-host interactions and best-in-class protocols.

• (-)-Blebbistatin as a Precision Tool for Mechanotransduction

  2026-07-07

  Explore how (-)-Blebbistatin empowers advanced mechanotransduction and cytoskeletal dynamics research through selective non-muscle myosin II inhibition. Uncover emerging assay strategies and novel insights from recent GPCR mechanosignaling studies.

• Practical Guide: HyperPFU™ High-Fidelity DNA Polymerase in P

  2026-07-06

  HyperPFU™ high-fidelity DNA polymerase addresses the technical challenges of accurate PCR amplification for long, GC-rich, or otherwise difficult DNA fragments. It is ideal for workflows requiring blunt-ended, high-fidelity PCR products but should not be used for protocols needing 3'-A overhangs or sticky ends.

• ETS1 Regulates Mitophagy via SENP2/HSPA8/FUNDC1 in BPD Model

  2026-07-06

  This study establishes ETS1 as a key regulator of mitophagy in bronchopulmonary dysplasia (BPD), demonstrating its protective effects through the SENP2/HSPA8/FUNDC1 axis. By elucidating ETS1's molecular mechanism in mitigating mitochondrial damage-induced autophagy, the work opens new avenues for targeted research into autophagy pathway modulation in lung disease.

• Sulfaphenazole Restores Perfusion and Reduces Pressure Injur

  2026-07-05

  This study demonstrates that Sulfaphenazole, a potent CYP2C9 inhibitor, rapidly restores tissue perfusion and mitigates both thermal and pressure injury severity in a murine model. The findings highlight its mechanistic role in reducing ischemia-reperfusion-induced damage, underscoring translational potential for vascular injury and wound healing research.

• Machine Learning Enhances mRNA Vaccine LNP Design with Dlin-

  2026-07-04

  This study pioneers the use of machine learning to predict efficacious lipid nanoparticle (LNP) formulations for mRNA vaccines, focusing on the role of ionizable cationic liposomes such as Dlin-MC3-DMA. The integration of computational modeling with experimental validation streamlines LNP optimization, setting a new standard for rational mRNA delivery system development.

• FK866 (APO866): NAMPT Inhibition for Hematologic Cancer Rese

  2026-07-03

  FK866 (APO866) is a potent, non-competitive NAMPT inhibitor used in hematologic cancer research. It depletes NAD and ATP selectively in malignant cells, induces caspase-independent cell death, and demonstrates robust in vivo antitumor activity. This article details its mechanism, applications, and limitations with up-to-date, verifiable data.

16297 records 1/1087 page Next 12345 下5页 Last page